MGNXHealthcare · BiotechnologyThe 7 Wall Street analysts covering MacroGenics, Inc. hold a median 12-month price target of $8.5 — +257.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores MacroGenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (90): The shares have been drifting up relative to others.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MGNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +257.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | B. Riley Securities | Maintains | Buy | — |
| 17 Aug 2026 | B. Riley Securities | Maintains | Buy | $9.00 → $11 |
| 20 Apr 2026 | Barclays | Maintains | Overweight | — |
| 20 Apr 2026 | Barclays | Maintains | Overweight | $4.00 → $6.00 |
| 10 Apr 2026 | B. Riley Securities | Upgrade | Buy | — |
| 10 Mar 2026 | Barclays | Maintains | Overweight | — |
| 3 Nov 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 17 Sept 2025 | Barclays | Assumes | Overweight | $3.00 |
| 15 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
| 20 May 2025 | B. Riley Securities | Maintains | Neutral | — |
| 14 May 2025 | Barclays | Maintains | Overweight | — |
| 14 May 2025 | Stifel | Maintains | Hold | — |
| 25 Mar 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 7 Nov 2024 | JMP Securities | Downgrade | Market Perform | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 18 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Aug 2024 | Citigroup | Maintains | Buy | — |
| 7 Aug 2024 | BMO Capital | Maintains | Market Perform | — |
| 1 Aug 2024 | BTIG | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MGNX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, MacroGenics, Inc. returned +40.8% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 71% of US stocks
Cheaper than 26% of US stocks
Cheaper than 66% of US stocks
Higher than 97% of US stocks
Higher than 73% of US stocks
Higher than 67% of US stocks
Higher than 18% of US stocks
Higher than 21% of US stocks
Higher than 6% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MacroGenics, Inc. has a market value of $155.4M and an enterprise value of $17.2M.
Revenue in the twelve months to 30 June 2026: $167.7M. The latest quarter grew 378.0% year on year.
Net income over the same four quarters: −$14.6M, a −8.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$65.5M.
Trailing P/E: 25.3×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MacroGenics, Inc. employs 293 people — $572K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MacroGenics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MacroGenics announced positive interim data from its ongoing Phase 2 LINNET study of lorigerlimab in patients with advanced clear cell gynecologic cancer. The data were presented at the ESMO 2026 Congress.
Why it matters — The interim study update provides MGNX watchers with news on the clinical development of lorigerlimab.
MacroGenics reported positive interim Phase 1 results for MGC026, a B7-H3-directed ADC, in patients with advanced solid tumors. The company said the results showed durable activity across a broad range of tumors and support expanding development into a front-line metastatic SCCHN combination study with pembrolizumab.
Why it matters — The update provides interim clinical data and outlines a planned development direction for MGC026, which may be relevant to MGNX watchers tracking its pipeline.
MacroGenics announced that the first patient has been dosed in its Phase 1 study of MGC030, an antibody-drug conjugate being evaluated in patients with advanced solid tumors. The company described MGC030 as directed against an undisclosed target.
Why it matters — The dosing marks the start of clinical evaluation of MGC030 in patients, following the company’s report of antitumor activity in preclinical models.
Zacks Investment Research compares MacroGenics (MGNX) and C4 Therapeutics (CCCC) with their sector based on performance so far this year. The excerpt does not provide performance results.
Why it matters — The comparison offers MGNX watchers context on the stock’s year-to-date performance relative to its sector, though the excerpt gives no results.
Seeking Alpha introduced 38 new analysts for September 2026 and featured their top picks and investment strategies. Highlighted ideas included Qualcomm, Teladoc, NewLake Capital Partners, and the TDAQ ETF; MacroGenics was not mentioned.
Why it matters — The article provides no company-specific information about MacroGenics, so it offers no direct update for MGNX watchers.
The 7 Wall Street analysts covering MacroGenics, Inc. have a median 12-month price target of $8.5, with estimates ranging from $4 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering MacroGenics, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MacroGenics, Inc. 62 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, MacroGenics, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +257.1% from the last close, and Ticker Nerd's factor model ranks MacroGenics, Inc. 62 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MacroGenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $11 over the next 12 months.
MacroGenics, Inc. returned +40.8% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer.
The most recent item we track (GlobeNewsWire, 26 Oct 2026): "MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer". MacroGenics announced positive interim data from its ongoing Phase 2 LINNET study of lorigerlimab in patients with advanced clear cell gynecologic cancer. The data were presented at the ESMO 2026 Congress.
MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing. The company’s work includes therapies designed to target specific tumor markers and modulate immune responses across a range of oncology settings. MacroGenics also maintains collaborations with other biotechnology and pharmaceutical companies to support development across its programs. Headquartered in Rockville, Maryland, MacroGenics plays a specialized role in the oncology market by advancing precision antibody technologies intended for use in difficult-to-treat cancers.
CEO Mr. Eric Blasius Risser · 293 employees · United States · https://www.macrogenics.com
